|Bid||2.45 x 1200|
|Ask||2.47 x 1200|
|Day's Range||2.41 - 2.48|
|52 Week Range||0.13 - 4.74|
|PE Ratio (TTM)||-2.41|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||19.75|
ROCKVILLE, Md., Sept. 21, 2017-- Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it will ...
Supinoxin™ is well tolerated and shows preliminary evidence of clinical activity in difficult to treat tumors. Preclinical studies on RX-3117 demonstrate additive and synergistic effects with Abraxane ...
ROCKVILLE, Md., Sept. 10, 2017-- Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced an update ...